Physician profile
Dipanjan Banerjee
NPI 1295787299
$331,474.56
in general payments reported to CMS, 2019-2025
36 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,044 · 2021: $6,034 · 2022: $39K · 2023: $78K · 2024: $95K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $209K · Travel and Lodging: $47K · Food and Beverage: $9,663 · Consulting Fee: $1,350 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,401.50 |
| Travel and Lodging | $47,124.17 |
| Food and Beverage | $9,663.14 |
| Consulting Fee | $1,350.00 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $226,537.94 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $28,436.33 | 2020-2025 | |
| Bridgebio Pharma, INC. | $20,268.20 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,686.06 | 2020-2025 | Jardiance |
| Medtronic Vascular, INC. | $10,444.99 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $9,305.67 | 2022-2025 | |
| Abbott Laboratories | $8,443.63 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $5,815.18 | 2021-2025 | Amvuttra |
| Abiomed | $3,702.68 | 2019-2025 | Impella |
| Lilly USA, LLC | $778.70 | 2023 | Jardiance, Mounjaro |
| Boston Scientific Corporation | $625.23 | 2019-2022 | |
| Cvrx, INC. | $400.86 | 2021-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $295.63 | 2020-2025 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $292.40 | 2019-2025 | Lifevest |
| Amgen INC. | $291.15 | 2023-2025 | Repatha, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.10 | 2024-2025 | Wegovy, Ozempic |
| Vifor Pharma, INC. | $189.99 | 2022-2024 | Veltassa |
| Medtronic, INC. | $189.53 | 2023 | Cobalt Dr Mri Surescan, Micra |
| Endotronix, INC. | $172.96 | 2021-2022 | |
| Sobi, INC | $169.70 | 2021-2023 | |
| Livanova USA, INC. | $161.41 | 2022-2023 | Protekduo |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Akcea Therapeutics, INC. | $156.10 | 2019-2021 | |
| Atricure, INC. | $148.55 | 2019 | |
| Kls-Martin L.P. | $99.25 | 2021 | |
| Merck Sharp & Dohme LLC | $84.94 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $58.98 | 2019-2021 | |
| Baxter Healthcare | $55.91 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Ethicon US, LLC | $53.31 | 2023 | Monocryl |
| Regeneron Healthcare Solutions, INC. | $47.61 | 2025 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $47.13 | 2024 | |
| Scpharmaceuticals INC. | $43.50 | 2023-2025 | |
| Lantheus Medical Imaging, INC. | $33.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.00 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $24.18 | 2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $22.55 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipanjan Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.